FGFR2 and metastatic malignant neoplasm in the lymph nodes: As compared to patients without lymph node metastasis, patients with lymph node metastasis were found to harbor significantly more mutations in two genes, POLE and TET2 (P<0.05, Figure 2C) and significantly more CN amplifications in 10 genes including ERBB2, CDK12, CCND1, RPS6KB2, AURKA, FGFR2, PRDM1, CDK4, CHD2, and FANCI (P <0.05, Figure 2D).